New drug shows promise for severe pneumonia patients in ICU
Disease control
Completed
This study tested an experimental drug called AON-D21 in 150 ICU patients with severe community-acquired pneumonia. The goal was to see if adding AON-D21 to standard care is safe and helps patients recover faster compared to a placebo. The trial is now complete, and results will …
Phase: PHASE2 • Sponsor: Aptarion Biotech AG • Aim: Disease control
Last updated May 15, 2026 11:56 UTC